Physician profile
Robert Newman
NPI 1164998472
$3,202.93
in general payments reported to CMS, 2019-2025
25 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $433 · 2022: $1,174 · 2023: $748 · 2024: $587 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,595.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $523.49 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $362.67 | 2022-2024 | |
| Celgene Corporation | $342.33 | 2021-2025 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $278.28 | 2023-2025 | Vanflyta, Injectafer |
| Merck Sharp & Dohme LLC | $224.92 | 2021-2024 | Keytruda, Prevymis, Recarbrio |
| E.R. Squibb & Sons, L.L.C. | $223.46 | 2022 | |
| Incyte Corporation | $156.53 | 2021-2022 | |
| Abbvie INC. | $125.00 | 2022 | |
| Stemline Therapeutics INC. | $125.00 | 2022 | |
| Karyopharm Therapeutics INC. | $123.23 | 2022 | |
| Blueprint Medicines Corporation | $97.54 | 2025 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $91.52 | 2021-2022 | |
| Kite Pharma, INC. | $82.36 | 2024-2025 | Yescarta |
| Rigel Pharmaceuticals, INC. | $76.98 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Emd Serono, INC. | $68.24 | 2023-2024 | Bavencio |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunocore Limited | $49.61 | 2023 | Kimmtrak |
| Bayer Healthcare Pharmaceuticals INC. | $42.81 | 2022 | |
| Amgen INC. | $39.59 | 2021-2022 | |
| Genzyme Corporation | $29.97 | 2025 | |
| Genmab U.S., INC. | $27.49 | 2023 | Tivdak |
| Cti Biopharma Corp. | $25.19 | 2022 | |
| Foundation Medicine, INC. | $23.82 | 2023 | Foundationone Liquid Cdx |
| Alexion Pharmaceuticals, INC. | $23.71 | 2023 | Soliris |
| Chiesi USA, INC. | $21.56 | 2024 | Ferriprox |
| Servier Pharmaceuticals LLC | $17.63 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.